Rapid Vitals for Monitoring Structural Heart Health
Groundbreaking innovation to acquire precise hemodynamics without drawing blood, surgeries, or imaging.
Clinical Partners
Use Cases
Hospitalized Patients
Remote Patient Monitoring
Clinical studies show that HEMOTAG Vitals can be use for in-home monitoring of heart failure patients, post-discharge.
Our system helps identify left ventricular dysfunction3 allowing the provider to monitor congestion4 remotely. Whereas traditional markers were found to be insufficient and misleading.
What we have learned from our studies
“HEMOTAG has shown benefit, allowing our team to detect abnormalities prior to symptom onset and ultimately help avoid hospitalization. Currently, the only other device available to provide this type of information to clinicians is CardioMEMS, which is an invasive device. The HEMOTAG device is an easy to use, non-invasive device that allows patients to feel like an active participant in their own care.”
How It Works
HEMOTAG Device
Rapid 30 second measurement using our quad-sensing technology that captures time synchronized vibrations.
HEMOTAG App
Intuitive, 1-touch, app acquires complex multimodal cardiac data and automatically uploads it to the cloud.
HEMOTAG Cloud
Accurate and actionable vitals and centralized monitoring tools available via the secure & HIPAA-compliant Clinician Dashboard.
1 Pino, Jesus E., et al. "Safety And Efficacy of The HemotagTm Recording Device To Detect Acutely Decompensated Heart Failure." Journal of Cardiac Failure 26.10 (2020): S45.
2 Ramos-Tuarez, Fergie, et al. "Non-invasive Evaluation of Cardiac Time Intervals By The HemotagTm Recording Device To Tailor Treatment of Acutely Decompensated Heart Failure." Journal of Cardiac Failure 26.10 (2020): S51.
3 De Armas, Yelenis Seijo, et al. "Utility of the HEMOTAG device in assessing left ventricular dysfunction." Journal of the American College of Cardiology 81.8_Supplement (2023): 437-437.
4 Dipan Uppal, et.al, Evaluation of the Degree of Decongestion Among Patients Admitted with Acutely Decompensated Heart Failure Utilizing the Novel HEMOTAG Cardiopulmonary Assessment System. HFSA Annual Scientific Meeting ‘23. Presentation 2022-A-1779. Oct 6, 2023.
